Craif and Nonagen Bioscience to collaborate to evaluate a novel cancer diagnostic test
Craif Secures Series B Funding
to Accelerate R&D for the Roll-Out of a New Cancer Test
Craif’s Urine Cancer Testing Initiative Featured in Nature Online Edition
Craif co-founder and Nanodevice Director, Dr. Yasui, gave a symposium lecture at the 41st Annual Meeting of the Japanese Society for Molecular Tumor Marker Research
Craif was featured in the CRDS research report as a major biotech venture in Japan.
Craif CTO, Dr. Ichikawa, made a presentation at the 81st Discussion Session of the Japan Society for Analytical Chemistry.
Craif present results of urine-based urothelial cancer detection at the American Association of Cancer Research (AACR) Annual Meeting 2021
Craif Inc. Announces Residency at JLABS @ Shanghai To Further Accelerate the Development of an Innovative Exosome Biomarker Discovery Platform
Forbes has announced that CEO Ryuichi Onose has been selected for the “Forbes 30 Under 30 Asia 2021” in the Healthcare & Science category
Research article on brain tumor detection from urinary microRNA was published